Vital Biosciences recently introduced VitalOne, their revolutionary blood testing technology on plenary stage at the American Association of Clinical Chemistry (AACC) Annual Meeting and announced total funding of $48 million. The innovative solution reimagines point-of-care testing through VitalOne to create a world where patients will not need to take additional time off from work, travel between their primary care doctor and a lab, or wait for days to discuss their results with their healthcare provider.
Vital Biosciences is an alumnus of the BDSP™ and CAAP® programs.